LIST OF CLINICAL TRIALS THAT ARE CURRENTLY RECRUITING PARTICIPANTS

Updated as of November 4, 2019

For studies that are active but not recruiting participants, please contact the Clinical Research Center. This list does not include studies under the Center for Regenerative Medicine.

Bipolar Disorder
A Phase 3, Multi Center, Four-Week, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents with Bipolar 1 Disorder (MANIC or MIXED)

Principal Investigator:   Dr. Elizabeth Rondain

Learn More

 

Breast Cancer
A Randomize, Double-blind, Parallel-group, Phase III trial to Compare the Efficacy, Safety, and Immunogenicity of TX-05 with Herceptin® in subjects with HER2 Positive Early Breast Cancer

Principal Investigator:   Dr. Regina Edusma-Dy

Learn More


Cervical Cancer
A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with and following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer (CALLA)

Principal Investigator:   Dr. Teresa Sy-Ortin

Learn More

 

Diabetes Mellitus 
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents with Type 2 Diabetes

Principal Investigator:    Dr. Sylvia Capistrano-Estrada


Learn More


Liver Cancer
Phase 1 Dose Escalation Trial to evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Reximmune-C2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes) in Refractory patients with primary Hepatocellular Carcinoma or Tumors Metastatic to the Liver

Principal Investigator:   Dr. Maria Belen Tamayo
Co-Investigator:              Dr. Regina Edusma-Dy
 

Lung Cancer


A Phase III Multicenter, randomized, Double Blind, Placebp-Controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subject with Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely resected (RO) Non-Small Lung Cancer (NSCLC)

Principal Investigator:   Dr. Maria Belen Tamayo

Learn More

A Randomized , Double Blind, Placebo Controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-Based Double Chemotherapy with or without Canakinumab as First Line Therapy for Locally Advanced of Metastatic Non Squamous and Non Small Cell Lung Cancer Subject (CANOPY-1U)

Principal Investigator:   Dr. Joseph Parra

Learn More

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently with Platinum-based Chemoradiation Therapy in Patients with Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III)

Principal Investigator:   Dr. Adrian Manapat

Learn More


Paroxysmal Nocturnal Hemoglobinuria
A Phase 3, Randomized, Multicenter, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Principal Investigator:   Dr. Teresita Dumagay

Learn More


Pulmonary Arterial Hypertension
A Multicenter, Open-Label, Randomized, Event-Driven Study to Assess Efficacy, Safety and Pharmacokinetics of Macitentan versus Standard of Care in Children with Pulmonary Arterial Hypertension.

Principal Investigator:   Dr. Aurelia Leus
Co-Investigator:              Dr. Rozaida Villon

Learn More


Systemic Lupus Erythematosus
A randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 study of Baricitinib in Patients with Systemic Lupus Erythematous

Principal Investigator:   Dr. Andrei Rhoneil Rodriguez

Learn More


Urothelial Cancer
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer (NILE)

Principal Investigator:   Dr. Maria Belen Tamayo

Learn More